Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

4(44.4%)

Phase 2

4(44.4%)

Phase 1

1(11.1%)

9Total

Phase 4(4)

Phase 2(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05677763Phase 4Active Not Recruiting

OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness

Role: lead

NCT05857930Phase 2Active Not Recruiting

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

Role: lead

NCT07178002Phase 4Active Not Recruiting

OM 85 to Prevent Respiratory Infections in Older At Risk Patients

Role: collaborator

NCT04186247Phase 2Terminated

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Role: collaborator

NCT06655272Phase 4Recruiting

OM 85 to Prevent Respiratory Infections in Older At Risk Patients

Role: collaborator

NCT06486662Phase 1Completed

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients

Role: lead

NCT06345014Phase 4Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Role: collaborator

NCT05305508Phase 2Completed

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

Role: collaborator

NCT05222516Phase 2Terminated

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Role: lead

All 9 trials loaded